Tadalafil Tablet
Product Images NDC 71335-1491

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1491). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351491)

Label for Tadalafil 20 mg oral tablet packaged by Bryant Ranch Prepack in Burbank, CA. The label notes comparison to Cialis 20 mg tablet by Ajanta Pharma Limited. It includes storage instructions to keep at room temperature 20°-25°C (68°-77°F) and a warning to keep all drugs out of reach of children. The product is RX only with a package size of 30 tablets and an NDC of 71335-1491.*

FDA Label Image

Tadalafil Fig8

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment duration. Two treatment groups are shown: Tadalafil 5 mg and placebo. The graph indicates a greater decrease in IPSS score for the Tadalafil 5 mg group compared to placebo, with a statistically significant difference at 12 weeks (p<0.01).*

FDA Label Image

Tadalafil Figure1

A set of four line graphs displaying the difference in blood pressure measurements (Tadalafil minus Placebo) over time in hours. The graphs illustrate changes in Standing Systolic Blood Pressure, Standing Diastolic Blood Pressure, Supine Systolic Blood Pressure, and Supine Diastolic Blood Pressure, with error bars shown for each time point.*

FDA Label Image

Tadalafil Figure2

A set of two line graphs displaying changes in systolic blood pressure (mmHg) over 24 hours post-dose for Tadalafil 20 mg with doxazosin 8 mg compared to placebo with doxazosin 8 mg. The top graph shows standing systolic blood pressure, and the bottom graph shows supine systolic blood pressure over time post-dose in hours.*

FDA Label Image

Tadalafil Figure3

Line chart showing the effect on systolic blood pressure (mmHg) over 12 hours after administration of 20 mg and 8 mg doses of tadalafil combined with doxazosin, compared to placebo with doxazosin. The x-axis represents time in hours, and the y-axis represents change in systolic blood pressure.*

FDA Label Image

Tadalafil Figure4

A pharmacokinetic graph showing plasma tadalafil concentration (µg/L) over time (hours) for different dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose following 5 consecutive days of administration. The plot includes error bars indicating variability.*

FDA Label Image

Tadalafil Figure5

A line graph comparing change from baseline in IPSS Total Score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The x-axis shows duration of treatment in weeks, and the y-axis shows change from baseline scores. The Tadalafil group shows a greater decrease compared to placebo, with a noted statistical significance (p<0.01).*

FDA Label Image

Tadalafil Figure6

Line graph depicting the change from baseline in IPSS Total Score over 12 weeks, comparing Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows the change in score. The graph indicates a greater decrease in IPSS score with Tadalafil versus placebo, with statistical significance marked at multiple points.*

FDA Label Image

Tadalafil Figure7

Line graph showing weeks of therapy on the x-axis (0, 4, 12, 26) and least squares mean change from baseline on the y-axis (-7.0 to 1.0). It compares Tadalafil/Finasteride and Placebo/Finasteride groups, with a difference line showing least-squares treatment difference. Data points with significance markers (a p<0.001, b p<0.05) are noted at weeks 4, 12, and 26.*

FDA Label Image

Tadalafil Structure

Chemical structure diagram of the active ingredient tadalafil, showing the molecular arrangement typical for this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.